Company Background - Dr Reddy's Labs

Dr. Reddy's Laboratories was came to on track in the year 1984 in Hyderabad, it was established by Dr Anji Reddy with an initial capital outlay of Rs.25 lakhs. It is a global pharmaceutical company with a presence in more than 100 countries and its doing well with wholly-owned subsidiaries in the US, UK, Russia, Germany and Brazil; joint ventures in China, South Africa and Australia; representative offices in 16 countries; and third-party distribution set ups in 21 countries. The company proven research capabilities and vertically integrated with a presence across the pharmaceutical value chain and it conducts research in the areas of diabetes, obesity, cardiovascular diseases, anti-infectives and inflammation. The Indian based company produces finished dosage forms, active pharmaceutical ingredients and biotechnology products which are marketed globally, with focus on India, US, Europe and Russia.

The company made its beginning with the manufacture of Active Pharmaceutical Ingredients and Intermediates (API) in 1984 and commenced operations with a single drug in a 60-tonne facility near Hyderabad, India. In 1986, the first consignment of that drug, Methyldopa, was shipped to West Germany. In 1988 the company acquired Benzex Laboratories Pvt. Limited to expand its Bulk Actives business and in the next year it acquired American Remedies Limited, a pharmaceutical company based in India. In the year 1993 the company established Dr. Reddy's Research Foundation and started its Drug Discovery program. The company has membership in WTO since April 1994 and in the same year 1994 the company Makes a GDR issue of USD 48 million.

The Company's Custom Pharmaceutical Services (CPS) business was formed in the year 2001, and in 2002 conducts its first overseas acquisition - BMS Laboratories Limited and Meridian Healthcare in UK, the company received ASIASTAR Award for Packaging Excellence 2002 for Mintop Forte - Customer Convenience Pack by Asian Packaging Federation in the year. Announced a 15-year exclusive product development and marketing agreement for OTC drugs with Leiner Health Products in the US by the company in the year 2003 and launched Ibuprofen, first generic product to be marketed under the "Dr. Reddy's" label in the US and it conferred WORLDSTAR Award for Packaging Excellence 2003 For Omez capsules pack with Anti-Counterfeiting Features. The acquisition of Trigenesis gives the company to access drug delivery technology platforms in the year 2004. Dr. Reddy's Lab increased focus point in CPS business after the acquisition of Roche's API manufacturing unit, Mexico in the year 2005 and in the same year the company acquired Roche's API Business at the state-of-the-art manufacturing site in Mexico with a total investment of USD 59 million. Announced the formation of Perlecan Pharma: India's First Integrated Drug Development Company and again announced India's first major co-development and commercialization deal for it's molecule Balaglitazone (DRF 2593), with Rheoscience. It made unique partnership for the commercialization of ANDAs with ICICI Venture, the Best Management Award 2005 by Labour Department, Govt. of Andhra Pradesh, India came to the company. In the year 2006 the company acquired Betapharm- the fourth-largest generics company in Germany for a total enterprise value of ? 480 million and received Finance Asia Achievement Awards 2006 for Best India Deal - acquisition of Betapharm. Dr. Reddy's Lab becomes No.1 pharmaceutical company in India in turnover and profitability as on 2007.

The appreciation and recognition is a role to boost, as part the company has received plenty of awards and applications already, continued that, the company got Pharma Excellence Awards 2006-07 under the category of Sustained Growth by The Indian Express, Dun & Bradstreet American Express in Corporate Awards 2007, Best Corporate Social Responsibility Initiative 2007 by BSE - India and Amity Leadership Award for Best Practices in HR in Pharmaceutical Sector. 4th HR Summit '08.

Dr Reddy's Laboratories has entered into a settlement agreement with Novartis Pharma AG on January 2008, which involves a stipulation of dismissal of the lawsuits in the United States relating to the Abbreviated New Drug Applications filed by the company for a generic version of rivastigmine tartrate capsules sold under the trade-name Exelon and in same month and year the company has launched Supanac (Diclofenac potassium immediate release 50 mg tablets) in India, increasing its offering in the Rs 2700 crores in NSAID market. Supanac is in-licensed from Applied Pharma Research (APR), Switzerland and is used for Acute Pain management. On February, 2008 the company has entered into an agreement with SkyePharma PLC to undertake a feasibility study of a product utilizing two of SkyePharma's proprietary drug delivery systems. Dr. Reddy's Laboratories announced that it has entered into a definitive agreement with The Dow Chemical Company to acquire a portion of Dowpharma Small Molecules business associated with its United Kingdom sites in Mirfield and Cambridge on 1st April 2008. In the same month of same year Dr.Reddy's Lab and 7TM Pharma has announced the signing of drug discovery collaboration on selected drug targets in the area of metabolic disorders. Under the terms of the agreement, Dr. Reddy's and 7TM Pharma will collaborate to identify clinical candidates for pre-selected targets. Both the parties will jointly develop these candidates from the pre-clinical stage up to Phase IIa (proof-of-concept). As on April 2008, the company has acquired Jet Generici Srl, a company engaged in the sale of generic finished dosages in Italy. The deal has been completed via Dr Reddy's Italian subsidiary.

To help people lead healthier lives by delivering affordable and accessible medication to all parts of the world and discovering, developing and commercializing innovative medicines that satisfy unmet medical needs are the two parallel objectives of Dr. Reddy's Laboratories Limited, and it is sustain path of the company to survive.